argenx NV ADR (ARGX)vsJazz Pharmaceuticals PLC (JAZZ)
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $55.09B
JAZZ
Jazz Pharmaceuticals PLC
$238.57
-0.62%
HEALTHCARE · Cap: $14.48B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7% more annual revenue ($4.74B vs $4.44B). ARGX leads profitability with a 31.4% profit margin vs 0.7%. JAZZ appears more attractively valued with a PEG of 0.96. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
JAZZ
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.4%
Fair Value
$2217.64
Current Price
$891.32
$1326.32 discount
Margin of Safety
+52.2%
Fair Value
$347.46
Current Price
$238.57
$108.89 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Strong operational efficiency at 23.5%
19.1% revenue growth
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 188.4x book value
3.2% earnings growth
ROE of 0.7% — below average capital efficiency
0.7% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : JAZZ
The strongest argument for JAZZ centers on PEG Ratio, Operating Margin, Revenue Growth. Revenue growth of 19.1% demonstrates continued momentum. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : JAZZ
The primary concerns for JAZZ are EPS Growth, Return on Equity, Profit Margin. A P/E of 1921.3x leaves little room for execution misses. Thin 0.7% margins leave little buffer for downturns.
Key Dynamics to Monitor
JAZZ carries more volatility with a beta of 0.33 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 56/100), backed by strong 31.4% margins and 62.6% revenue growth. JAZZ offers better value entry with a 52.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Jazz Pharmaceuticals PLC
HEALTHCARE · BIOTECHNOLOGY · USA
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?